drugset / Trial / NCT04060758
Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multi-centre, open label, interventional, comparative, phase I study to identify a safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who have Primary Open Angle Glaucoma.
Timeline
- Start
- 2020-03-11
- Primary completion
- 2025-05-13
- Completion
- 2025-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latanoprost | Small molecule | 14.7 ug | Other |
| Subject | Latanoprost | Small molecule | 26.6 ug | Other |
| Subject | Latanoprost | Small molecule | 35.5 ug | Other |